Merck & Co Inc.

22 sept. 2026, 23:06 UTC

Merck & Co Inc's WINREVAIR™ product label update receives FDA approval, contributing to a slight gain in after-market hours following earlier declines.

21 sept. 2026, 23:06 UTC

Merck's KEYTRUDA QLEX™ injection has been approved for subcutaneous use in Japan, with the stock remaining roughly flat in after-market trading.

18 sept. 2026, 23:06 UTC

Merck & Co Inc declined in after-market trading, moving from a small gain to a modest loss and remaining below its 20-day moving average.

17 sept. 2026, 20:07 UTC

Merck's shares are advancing following positive Phase 3 trial results for its collaboration with Moderna on a personalized mRNA cancer therapy for melanoma.

16 sept. 2026, 23:51 UTC

Merck & Co Inc is advancing in after-market trading, supported by positive U.S. retail sales data, despite ongoing concerns over TIC flows and Treasury yields.

15 sept. 2026, 23:01 UTC

Merck & Co Inc shares are lower in after-market hours. Broader market sentiment is impacted by a significant decline in the New York Empire State Manufacturing Index.

14 sept. 2026, 23:06 UTC

Merck & Co Inc shares rose in after-market trading following Monday's close, despite earlier declines and no specific news to explain the movement.

11 sept. 2026, 19:36 UTC

Merck & Co Inc shares are declining amid broader market trends following inflation data that heightened interest rate hike speculation. No specific company news was identified.

10 sept. 2026, 20:07 UTC

Merck & Co Inc shares are lower today despite HSBC raising its price target to $172 and noting insider buying activity.

9 sept. 2026, 19:36 UTC

Merck & Co. shares are lower after a court upheld Medicare's drug-price negotiations, raising concerns about future prescription drug spending.

8 sept. 2026, 23:06 UTC

Merck & Co. shares are higher after Karim Mikhail's appointment to lead the FDA's Center for Biologics Evaluation and Research, boosting the company's regulatory reputation.

4 sept. 2026, 23:05 UTC

Merck & Co Inc shares are higher in after-market trading, despite no specific news. Broader market signals show mixed economic indicators and rising Treasury yields.

3 sept. 2026, 23:05 UTC

Merck & Co Inc shares are lower in after-market hours, reflecting a slight decline since Thursday's close amid broader market gains.

2 sept. 2026, 19:46 UTC

Merck & Co Inc is rising following positive results from the ATLAS-UC Phase 3 trial, which met its primary endpoint of clinical significance.

1 sept. 2026, 23:07 UTC

Merck & Co Inc. shares were roughly flat during after-market hours, with no specific company news identified amid broader market fluctuations driven by rising oil prices.

31 août 2026, 23:16 UTC

Merck & Co Inc shares are trading higher in after-market hours. Broader market sentiment is influenced by escalating geopolitical tensions and inflation concerns.

28 août 2026, 23:01 UTC

Merck & Co Inc shares are higher in after-market trading, supported by rising Treasury yields and trading above their 20-day moving average.

27 août 2026, 23:01 UTC

Merck & Co Inc. shares are higher in after-market trading, reflecting routine performance despite three consecutive lower sessions. The stock remains above its 20-day moving average.

26 août 2026, 23:11 UTC

Merck & Co Inc is higher in after-market hours, reflecting broader market gains. The stock remains above its 20-day moving average.

25 août 2026, 23:06 UTC

Merck & Co Inc reached all-time highs in after-market trading, gaining over $6 amid positive social media sentiment and broader market dynamics.

24 août 2026, 23:16 UTC

Merck & Co Inc shares are higher in after-market trading, showing stable performance since Monday's close. The stock remains above its 20-day moving average.

21 août 2026, 19:31 UTC

Merck & Co Inc shares are higher today as Goldman Sachs and Morgan Stanley upgraded their ratings and raised price targets, citing confidence in cancer treatments.

20 août 2026, 19:31 UTC

Merck & Co Inc shares are lower today following downgrades from RBC Capital and UBS, with both firms setting a price target of $150.

19 août 2026, 23:41 UTC

Merck & Co Inc shares declined in after-market trading despite positive Phase 3 trial results for its mRNA-based therapy combined with KEYTRUDA.

17 août 2026, 19:36 UTC

Merck & Co Inc shares are higher during Monday's session, reflecting a slight cumulative return since Friday's close amid rising long-term Treasury yields.

15 août 2026, 00:01 UTC

Merck & Co Inc shares are lower in after-market hours following notable volatility during the session, despite mixed global market performance.

14 août 2026, 23:21 UTC

Merck & Co Inc shares are lower in after-market trading following a decline in U.S. retail sales for July, raising concerns about consumer demand.

13 août 2026, 23:06 UTC

Merck & Co Inc. shares were roughly flat in after-market hours, remaining above their 20-day moving average after three consecutive sessions of higher finishes.

12 août 2026, 19:56 UTC

Daiwa Capital upgraded Merck to Outperform, raising the price target to $143. The stock remains higher since Tuesday's close amid positive FDA news.

11 août 2026, 19:36 UTC

Merck & Co. shares are lower today despite Argus Research maintaining a Buy rating and raising the price target to $145.